Volume | 308,060 |
|
|||||
News | - | ||||||
Day High | 42.865 | Low High |
|||||
Day Low | 41.69 |
Company Name | Stock Ticker Symbol | Market | Type |
---|---|---|---|
Crinetics Pharmaceuticals Inc | CRNX | NASDAQ | Common Stock |
Open Price | Low Price | High Price | Close Price | Prev Close |
---|---|---|---|---|
42.49 | 41.69 | 42.865 | 42.29 |
Trades | Volume | VWAP | Dollar Volume | Avg Volume | 52 Week Range |
---|---|---|---|---|---|
4,803 | 308,060 | $ 42.40 | $ 13,061,985 | - | 15.76 - 49.5799 |
Last Trade Time | Type | Quantity | Stock Price | Currency |
---|---|---|---|---|
15:14:45 | 2 | $ 42.07 | USD |
Crinetics Pharmaceuticals (CRNX) Options Flow Summary
Crinetics Pharmaceuticals Inc Financials
Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
---|---|---|---|---|---|---|
2.93B | 69.60M | - | 4.01M | -214.53M | -3.08 | - |
Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
---|---|---|---|---|---|
- | - | - | - |
Crinetics Pharmaceuticals News
Loading Messages....
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical CRNX Price Data
Period | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
---|---|---|---|---|---|---|---|
1 Week | 42.36 | 45.26 | 41.05 | 43.24 | 555,916 | -0.28 | -0.66% |
1 Month | 46.70 | 49.5799 | 41.05 | 45.67 | 798,758 | -4.62 | -9.89% |
3 Months | 36.76 | 49.5799 | 35.70 | 42.72 | 815,107 | 5.32 | 14.47% |
6 Months | 28.48 | 49.5799 | 25.75 | 37.73 | 822,004 | 13.60 | 47.75% |
1 Year | 18.50 | 49.5799 | 15.76 | 30.62 | 906,686 | 23.58 | 127.46% |
3 Years | 17.30 | 49.5799 | 15.23 | 26.51 | 493,638 | 24.78 | 143.24% |
5 Years | 25.00 | 49.5799 | 10.63 | 25.22 | 341,534 | 17.08 | 68.32% |
Crinetics Pharmaceuticals Description
Crinetics Pharmaceuticals Inc is a clinical-stage pharmaceutical company focused on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors. |